Keyphrases
Cost-effectiveness
100%
Positron Emission Tomography
100%
Computed Tomography
100%
Stage I Lung Cancer
100%
Mediastinoscopy
100%
Clinical Stage I
71%
Mediastinal Lymph Node Metastasis
57%
N2 Disease
42%
Metastasis
28%
Lung Cancer
28%
Adjuvant Therapy
28%
Sensitivity Analysis
28%
Decision Analysis
28%
Life-years Gained
28%
Benign Nodule
28%
Preoperative Staging
28%
Resection
14%
Optimal Management
14%
Long-term Survival
14%
Resection Specimen
14%
Survival Benefit
14%
Induction Therapy
14%
Positron Emission Tomography-computed Tomography (PET-CT)
14%
Lung Cancer Patients
14%
Pathology Report
14%
Occult
14%
Patient Management
14%
Lung Tumor
14%
Pathological Stage
14%
Thoracic Surgery
14%
Decision-analytic Model
14%
Life Expectancy
14%
Operative Report
14%
Post-resection
14%
Decision Model
14%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Positron Emission Tomography-Computed Tomography
100%
Lung Cancer
100%
Mediastinoscopy
100%
Clinical Stage
71%
Prevalence
57%
Lymph Node Metastasis
57%
Mediastinal Lymph Node
57%
Diseases
42%
Health Care Cost
28%
Metastatic Carcinoma
28%
Adjuvant Therapy
28%
Long Term Survival
14%
Thorax Surgery
14%
Lung Tumor
14%
Life Expectancy
14%
Surgery
14%